Treatment effects of human amnion-derived mesenchymal stem cells for skin lesions and metastatic pulmonary calcification in calciphylaxis patients - case series and literature review

Ren Fail. 2025 Dec;47(1):2516207. doi: 10.1080/0886022X.2025.2516207. Epub 2025 Jun 15.

Abstract

Background: Calciphylaxis, also termed calcific uremic arteriolopathy (CUA) in patients with end-stage kidney disease (ESKD), is a rare and fatal condition characterized by cutaneous ischemic necrosis.

Methods: Three patients with calciphylaxis and metastatic pulmonary calcification (MPC) were treated with human amnion-derived mesenchymal stem cells (hAMSCs). Effects were evaluated using the Visual Analogue Scale (VAS), modified Bates-Jensen Wound Assessment Tool for CUA (BWAT-CUA), wound quality of life questionnaire (Wound-QoL), and histological analysis. MPC was assessed by high-resolution CT (HRCT) and 99ᵐTc-methylene diphosphonate (99ᵐTc-MDP) bone scans.99ᵐTc-labeled macroaggregated albumin (99ᵐTc-MAA) pulmonary perfusion imaging was conducted for the first time in patients with MPC.

Results: Three patients exhibited wound healing and improvement in skin symptoms. Two months before CUA, asymptomatic MPC was detected in Patient 1, who was treated with hAMSCs for 15 months. The condition progressed to chest pain and dyspnea. HRCT and 99ᵐTc-MDP bone scans showed worsening calcification, particularly in the upper and mid-thoracic lobes.99ᵐTc-MAA pulmonary perfusion imaging revealed impaired or absent blood perfusion in the areas of metastatic calcification. Patient 1 died from respiratory failure. Patients 2 and 3 had asymptomatic MPC at calciphylaxis diagnosis. After 2 months of treatment, Patient 2, showed no significant imaging improvement and passed away 6 months after discontinuing hAMSC treatment. Patient 3 has shown no significant progression of pulmonary lesions and continues hAMSC therapy.

Conclusion: We reported personalized early, noninvasive diagnosis and regenerative treatments for calciphylaxis patients with MPC. Although the current hAMSC treatment regimen is effective for skin lesions, its impact on MPC requires further investigation.

Keywords: 99ᵐTc-MAA pulmonary perfusion imaging; 99ᵐTc-MDP; Calciphylaxis; calcific uremic arteriolopathy; human amnion-derived mesenchymal stem cells; metastatic pulmonary calcification.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Aged
  • Amnion* / cytology
  • Calcinosis* / etiology
  • Calcinosis* / therapy
  • Calciphylaxis* / complications
  • Calciphylaxis* / etiology
  • Calciphylaxis* / pathology
  • Calciphylaxis* / therapy
  • Female
  • Humans
  • Kidney Failure, Chronic* / complications
  • Kidney Failure, Chronic* / therapy
  • Lung Diseases* / etiology
  • Lung Diseases* / therapy
  • Male
  • Mesenchymal Stem Cell Transplantation* / methods
  • Mesenchymal Stem Cells / cytology
  • Middle Aged
  • Quality of Life
  • Skin / pathology
  • Tomography, X-Ray Computed
  • Treatment Outcome
  • Wound Healing